home
investors
newsroom
licensing
careers
contact us
About Us
Our Values
Leadership
How We Operate
Views and Positions
Merck/Schering-Plough Merger
Our History
Corporate Responsibility
Ethics and Transparency
Access
Environment
Community
Research
Pipeline
Discovery & Development
Products
Vaccines
Prescription Products
Consumer Products
Animal Health
Prescribing Information
INVESTED IN
YOUR FUTURE
Financials
Annual Reports, Proxy Statements, and Form 10-K
SEC Filings & Certifications
Earnings Releases
Quarterly Financials
Stock Information
Stock Chart
Historical Price Lookup
Stock Splits
Cash Dividend History
Investment Calculator
Partnerships
Events & Presentations
Stockholder Services
Information Request
Contact Us
LATEST NEWS
Dec. 1, 2009
FDA Approves ZEGERID OTC™ for Over-the-Counter Treatment of Frequent Heartburn
Dec. 1, 2009
U.S. Department of Health & Human Services Recommends Merck's First-in-Class Integrase Inhibitor ISENTRESS® (raltegravir) Tablets, in Combination Therapy, as a Preferred Regimen for Treatment-Naïve Patients with HIV-1 Infection
Nov. 30, 2009
Merck Argues VIOXX® Case before U.S. Supreme Court
More news
Print
Share
Text Size
Product Pipeline
Learn more
Related Information
2008 Merck Annual Report
2008 Schering-Plough Annual Report
Corporate Responsibility Report
Podcast
